Search This Blog

Friday, September 25, 2026

Piker joins in anti-Israel chant ‘From the river to the sea’ at Cornell University event

 Left-wing darling Hasan Piker joined a loud chant of the anti-Israeli slur “from the river to the sea” at the end of his controversial star appearance at New York’s Cornell University, shocking video shows.

The New Jersey-born socialist provocateur, who sparked fury with his 2019 claims that America deserved 9/11, joined in as most of his audience Sage Chapel at Thursday’s event proudly chanted the call, which is widely seen as hate speech implying the destruction of Israel.

It came after Piker called on the audience of the Ivy League institution’s “Students Not Bombs” campaign to “maintain revolutionary optimism, always.”

Hasan Piker joined pro-Palestine supporters with a chant of “from the river to the sea” during an appearance at Cornell University.HasanAbi/Twitch

“On that note, if you want to join me in a protest chant,” the event moderator, who had a keffiyeh draped around her, told the audience and her star guest.

“From the river to the sea…” the moderator chanted, with the audience loudly responding, “Palestine will be free.”

Piker, 35, raised his microphone to his mouth and was heard mumbling his part of the response,

The antisemitic slur, which calls for the eradication of Israel, was repeated two more times before a man sitting on the benches led a chant of “Free, free Palestine,” with Piker again raising his mic and mumbling in response.

The streamer was met with loud cheers and treated like a rock star as he left.

Piker spoke at the event, which was organized by the university’s Student for Justice in Palestine and Young Democratic Socialists of America movements, on the same day that Israeli Prime Minister Benjamin Netanyahu shredded New York City mayor Zohran Mamdani at the United Nations General Assembly for his friendship with the streamer.

Footage of the chants prompted critics to label Cornell a “bastion of hate.”

“Pretty disappointed in Cornell for this one,” one horrified viewer said.

Cornell University has come under fire over Piker’s appearance.HasanAbi/Twitch

“Disgusted that Cornell gave Hasan Piker a platform today,” a graduate said. “As an alum, I am embarrassed and outraged. Cornell, what are you thinking? You can do better.”

Others were stunned that the event was held in Sage Chapel, which was the first nonsectarian chapel at a US college when it opened in 1875.

In the build-up to Piker’s appearance, the university’s Hillel chapter said the influencer’s views “ go against our values as Americans and Jews,” and described his “hateful rhetoric” as “repulsive.”

A petition by SAFE Campus, a Jewish advocacy group, urged Cornell, state and federal officials to call off the event.

The moderator celebrated after the event with the socialist provocateur.HasanAbi/Twitch

The petition alluded to Cornell claims that it had taken “a clear and strong stand” against antisemitism following the October 7, 2023, terror attacks. 

Piker’s appearance came less than a year after the university agreed to pay $60 million in a settlement to the Trump administration to resolve investigations into campus antisemitism. 

The agreement resulted in around $250 million in federal research funding being unfrozen. 

Piker justified the Oct. 7 Hamas terror attacks, saying the massacre that killed roughly 1,200 innocents was a “direct consequence of Israeli actions” and that “it doesn’t matter if f–king rapes happened on Oct. 7.”

Piker, the nephew of Cenk Uygur, the founder of the Young Turks, has raised eyebrows with his outlandish perspectives on the Middle East.

Earlier this month, the streamer, who has previously spoken at University of South California and Dartmouth University, wildly claimed that the region “would be more stable” if Iran had nuclear weapons.

“I think Iran, much like any other sovereign nation, has a right to defend itself, regardless of its domestic policies,” he told Axios correspondent Alex Thompson.

Piker has stumped with the Michigan US Senate candidate, Abdul El-Sayed, during the primary election and said far-left New York congresswoman, Alexandria Ocasio-Cortez, is his preferred pick for the 2028 presidential election.

https://nypost.com/2026/09/25/us-news/hasan-piker-joins-in-anti-israel-chant-of-from-the-river-to-the-sea-at-cornell-university-event/

'Houthis said to vow not to strike EU ships'

 Houthis sent a letter to the European Union's foreign policy service on September 10, promising not to target its vessels, the Financial Times reported on Friday, citing two diplomats familiar with the matter. They said the Yemeni militant group insisted that its goal is not to disrupt maritime traffic and that its conflict with Saudi Arabia will not affect freedom of navigation through the Bab al-Mandeb Strait.

The sources added that the EU is in talks with Saudi Arabia about the possibility of "combining maritime task forces" to protect vessels traversing the strait to and from the Red Sea. It is currently unclear whether the EU is also considering supporting Saudi Arabia against the Houthis.

https://breakingthenews.net/Article/Houthis-said-to-vow-not-to-strike-EU-ships/67178691

'Gates: AI powerful enough to cause 1B deaths'

 Billionaire and Microsoft co-founder Bill Gates said in an interview with NBC News set to be aired in full on Sunday that artificial intelligence (AI) is "powerful enough to drive events that, you know, cause a billion deaths" and insisted the technology needs to be government-regulated.

"No one thinks self-regulation is enough," Gates told NBC News' 'Meet the Press.' "You need law enforcement and the politicians to get into the discussion about what safeguards and monitoring look like ... And that has to be a required thing. And it will be a little bit of overhead for the industry, but not a dramatic slowing of what they're doing," he added.

The comments come after several AI executives, including OpenAI CEO Sam Altman, Anthropic CEO Dario Amodei and SpaceX CEO Elon Musk, called for a slowdown in the development of the technology, warning of safety risks. Meanwhile, US President Donald Trump dismissed their concerns, insisting that claims that AI could take over the world are a "hoax."

https://breakingthenews.net/Article/Gates:-AI-powerful-enough-to-cause-1B-deaths/67178680

Russian strikes shut Ukraine’s biggest steelmaker

 





Steelmaker ArcelorMittal said on Friday it could not restart production at Ukraine’s largest steel plant after a series of missile strikes, the latest economic setback from Russia’s escalating air campaign.The Luxembourg-based firm said it had informed the Ukrainian government that “safe and sustainable” operations were not possible after four strikes in five weeks caused extensive damage and killed five workers at the southeastern plant.




Its shutdown is another blow to Ukraine’s steel sector, a key industry that accounts for 15% of the country’s exports but has come under pressure from Russian attacks and restrictions from the EU, its top trading partner.



“It is with deep regret that we have concluded that we are no longer able to safely operate ArcelorMittal Kryvyi Rih,” subsidiary CEO Mauro Longobardo said in a statement.





Russia has intensified attacks across Ukraine in recent months using ballistic missiles and jet-powered drones that Kyiv’s military lacks the resources to intercept.

Targets have included businesses, logistics networks, Black Sea port facilities and civilian infrastructure.

A drone strike on central Kyiv on Friday killed a 14-year-old boy in an attack President Volodymyr Zelenskiy described as “absolutely savage and sickening”.

Zelenskiy said a separate strike killed one person at a postal facility in the Black Sea port of Odesa, while a medical clinic in the southeastern city of Zaporizhzhia was hit while people were inside.

Russia denies deliberately targeting civilians in the war, triggered by its full-scale invasion of Ukraine in 2022.






The United Nations said on Friday its monitoring mission in Ukraine had recorded at least 200 civilian deaths in September from attacks that also damaged “homes, hospitals, shops and workplaces”.

Russia’s defence ministry said its forces had carried out overnight drone strikes on Ukrainian defence industry facilities, logistics centres and vessels used by Kyiv’s armed forces.

Ukraine has also stepped up attacks on Russia, targeting defence and energy facilities as well as major online retailers in an effort to undermine revenues and support for Moscow’s war effort.

SUFFERING STEEL INDUSTRY






ArcelorMittal, whose Kryvyi Rih plant produced 1.7 million metric tons of steel in 2025, said it expected to book a non-cash impairment charge of around $1 billion.

The plant’s operations also include iron ore mines, which produced 7.6 million tons of iron ore in 2025, according to the company’s annual report.






“We are discussing the future of the plant with the Government of Ukraine and will focus on preserving the infrastructure, so when peace finally returns, options for restarting production remain available,” said Longobardo.

ArcelorMittal shares were up 2.2% at 1021 GMT, outperforming a 0.6% rise in the pan-European STOXX 600 index.

Ukrainian steelmaker Metinvest, owned by the country’s richest person, has also been repeatedly targeted by Russian attacks.

Earlier this month, a ballistic missile strike on its Kamet pig iron and steel plant in the eastern Dnipropetrovsk region forced a halt to operations.

Zaporizhstal, its nearly century-old mill, temporarily closed in August after a strike that killed seven workers.

The impact of the shutdown on ArcelorMittal and global steel markets is likely to be limited because the Kryvyi Rih plant had already been operating at significantly reduced capacity since 2022, a Kepler Cheuvreux analyst told Reuters.

Investors appeared to have anticipated the decision after recent strikes, while the $1 billion impairment charge was relatively modest for a company of ArcelorMittal’s size, equivalent to roughly 2% of its market capitalisation, the analyst said.


https://theprint.in/world/russian-strikes-shut-ukraines-biggest-steelmaker/3053479/

Netanyahu speech: Countires that stayed in the room

 Representatives of the United States, Germany, Argentina, Hungary, Serbia, Ukraine, Czechia and Greece remained in the General Assembly hall during Netanyahu’s address.

The United Kingdom, France, Ireland, Belgium and Norway, whose relations with Israel have faced increasing tensions over Gaza, also kept representatives in the chamber, as did the European Union delegation.

China, which has repeatedly criticised Israel’s actions in Gaza and the occupied West Bank, was represented by a single diplomat.

Delegations from the United Arab Emirates and Bahrain, which normalised relations with Israel under the Abraham Accords, also remained in their seats.

Other countries represented during the speech included Australia, Austria, Canada, Portugal, Poland, Denmark, Romania, Slovakia, Estonia, Lithuania, Luxembourg, Iceland, Azerbaijan, Kazakhstan, Mexico, Kenya and El Salvador.

https://tribune.com.pk/story/2631357/inside-the-un-walkout-who-left-and-who-stayed-for-netanyahus-speech

Novartis bets up to $900M for radioligand therapy from China’s BoomRay

 

Novartis is the current radiopharma leader with two FDA-approved therapies in Pluvicto and Lutathera.

Novartis has exclusively licensed a preclinical radioligand therapy from Suzhou-based BoomRay Pharmaceuticals in a deal that could reach up to $900 million.

The deal value potential encompasses an undisclosed upfront payment from Novartis, as well as possible development, regulatory and sales milestone payments BoomRay could receive, according to a Tuesday news release. The Chinese biotech is also eligible to receive royalties on future net sales.

Novartis declined to disclose specifics about the newly licensed asset’s indication or targets, but said in an email to BioSpace that BoomRay’s preclinical candidate “aligns with our strategy to expand and strengthen our radioligand therapy portfolio with high-potential, complementary programs.”

Novartis has consistently led in the radiopharma space, with two FDA-approved therapies: Lutathera, approved for gastroenteropancreatic neuroendocrine tumors, and Pluvicto, indicated for prostate cancer. The products made $816 million and nearly $2 billion in revenues last year, respectively.

The pharma is also working on an investigational next-gen Actinium-225-based therapy for metastatic castration-resistant prostate cancer (mCRPC), currently in Phase 3 development with an FDA submission planned for 2028.

Earlier this year, Novartis’ investigational radiopharma pipeline was hit by a setback when the pharma discontinued a mid-stage asset based on Lutetium-177 as “early clinical data did not support advancing it to the next stage of development,” a spokesperson told BioSpace at the time.

As for Novartis’ new partner BoomRay, the China company takes an integrated approach to diagnosis and treatment, using its radio-coupled assets to identify patients most likely to benefit from intervention and then delivering tumor-targeting radioligand therapies (RLT), according to an English translation of the biotech’s website.

Novartis’ deal with BoomRay prefaces what intelligence platform Sleuth predicted to be an increase in radioligand licensing deals between Western and Chinese companies in 2027. This projected growth reflects the rise of Western companies that have established their own supply chains that can support radioligand therapies licensed from China. These assets are radioactive, meaning they have specific handling and regulatory requirements and must reach patients before the isotope decays.

“The value of China’s pipeline accrues to whoever in the West owns the RLT infrastructure,” Sleuth noted.

Elsewhere in the radiopharma space, Telix earlier this week acquired ITM Isotope Technologies Munich for $1.65 billion up front—plus up to $700 million in milestones—in what William Blair called a “supercritical” deal since it bolsters the Australian developer’s manufacturing capabilities. ITM’s radiopharma asset was rejected last month over manufacturing problems.

https://www.biospace.com/deals/novartis-bets-up-to-900m-for-radioligand-therapy-from-chinas-boomray

Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics

 

Genentech’s agreement with Earendil Labs came the same day its parent company, Roche, inked a cardiometabolic and renal deal with Atavistik Bio for up to $2 billion.

Genentech is paying $55 million upfront to work with AI biotech Earendil Labs to discover and develop several bispecific antibody cancer therapies.

The heavily backloaded deal could top $1.5 billion, encompassing the pharma’s upfront commitment plus development, regulatory and sales milestones, according to a Thursday release. Earendil could also receive tiered royalties on net sales if products stemming from the alliance make it to market.

Under the terms of the agreement, Earendil will lead antibody discovery and early clinical research work for certain pre-agreed target combinations. Genentech will then take charge of any global clinical development and commercialization activities.

The partners will work on oncology indications but have yet to publicly identify target diseases. “We continue to follow the science and invest in emerging breakthrough areas and assets with best-in-class potential that could deliver broad patient benefit in the near, mid- and long-term,” a Roche spokesperson told BioSpace over email.

Earendil uses an AI-driven platform that can generate antibody sequences to produce next-generation biologic therapies. In March, the biotech raised an eye-popping $787 million in a private funding round backed by Sanofi and the Biotech Development Fund, which is created by Hillhouse and Pfizer, among others. Sanofi in April 2025 also fronted $125 million to license two bispecific antibodies from Earendil for autoimmune conditions and inflammatory bowel diseases. That deal included up to $1.72 billion in milestones.

For Genentech’s parent, Roche, the Earendil deal could help deepen the pharma’s bispecific portfolio. One of the pharma’s biggest products is Vabysmo, an antibody that binds to two proteins—VEGF-A and angiopoietin-2—for the treatment of various eye diseases. Last year, Vabysmo generated CHF 4.1 billion ($4.95 billion).

In cancer, Roche owns the CD20xCD3 T-cell engaging bispecific therapies Lunsumio, for relapsed or refractory follicular lymphoma, and Columvi, for relapsed or refractory diffuse large B cell lymphoma or large B cell lymphoma.

Roche inked a deal of its own on Thursday, linking up with Atavistik Bio for $70 million upfront to develop small-molecule drugs for cardiovascular, renal and metabolic diseases in a deal that could reach nearly $2 billion. Earlier this month, Roche put up to $1 billion on the line to work with Dualitas Therapeutics on next-generation bispecific antibodies. Other recent Roche deals include a DualityBio pact for potentially more than $1 billion and an agreement with Hanmi Pharm for up to $2.3 billion.

https://www.biospace.com/deals/genentech-makes-1-5b-deal-with-ai-heavyweight-earendil-for-cancer-bispecifics